Recombinant Human LILRA5/CD85f/LIR-9 Protein, CF

When Recombinant Human LILRA5/CD85f is coated at 2 µg/mL,Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # 914-AN) binds with an ED50 of0.1-0.6 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human LILRA5/CD85f/LIR-9 Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human LILRA5/CD85f is coated at 2 µg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # 914-AN) binds with a typical ED₅₀ of 0.1-0.6 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human LILRA5/CD85f protein
  Gly42-Arg268, with a C-terminal 6-His tag
• Accession #: A6NI73
• N-terminal Sequence: Gly42
• Protein/Peptide Type: Recombinant Proteins
• Gene: LILRA5
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 26 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 35-50 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human LILRA5/CD85f/LIR-9 Protein, CF

• CD85 antigen-like family member F
• CD85
• CD85f antigen
• CD85f
• ILT11
• ILT-11
• ILT11CD85f
• Immunoglobulin-like transcript 11
• leukocyte Ig-like receptor 9
• Leukocyte immunoglobulin-like receptor 9
• leukocyte immunoglobulin-like receptor subfamily A member 5 soluble
• leukocyte immunoglobulin-like receptor subfamily A member 5
• leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 5
• leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains)
• LILRA5
• LILRB7
• LIR9
• LIR-9
• LIR9immunoglobulin-like transcript 11 protein
• member 7

Background

The leukocyte immunoglobulin-like receptors (LILR) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIRs) (1). Human LILRA5, also known as ILT11, LIR-9, and CD85f, consists of a 227 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 10 aa cytoplasmic tail (2). The ECD contains two Ig-like domains (3), and the transmembrane segment contains a positively charged aspartic acid residue which may mediate its association with the signaling molecule, FcR common gamma chain (4). Alternative splicing generates additional isoforms with a 12 aa deletion within the signal peptide and/or a 27 aa substitution for the C-terminal 61 residues. This substitution encompasses both the transmembrane and cytoplasmic regions. LILRA5 is expressed by monocytes, macrophages, and neutrophils (2, 4). It is found as an approximately 40 kDa molecule on the cell surface, while a soluble 25 kDa form can be released into the synovial fluid of rheumatoid arthritis patients (2, 4). Cross-linking of LILRA5 on monocytes induces the expression of pro-inflammatory cytokines (IL-1 beta, IL-6, TNF-alpha) as well as the anti-inflammatory IL-10 (2, 4). R&D Systems in-house testing indicates that LILRA5 binds to Angiopoietin-like 7, consistent with the demonstrated functional interactions between other members of these protein families (5).

1. Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
2. Borges, L. et al. (2003) Blood 101:1484.
3. Shiroishi, M. et al. (2006) J. Biol. Chem. 281:19536.
4. Mitchell, A. et al. (2008) Eur. J. Immunol. 38:3459.
5. Zheng, J. et al. (2012) Nature 485:656.

Bioinformatics

• Gene Symbol: LILRA5
• Uniprot:
  • A6NI73(Human)